Glycogen Synthase Kinase-3 and Mammalian Target of Rapamycin Pathways Contribute to DNA Synthesis, Cell Cycle Progression, and Proliferation in Human Islets by Liu, Hui et al.
Glycogen Synthase Kinase-3 and Mammalian Target of
Rapamycin Pathways Contribute to DNA Synthesis, Cell
Cycle Progression, and Proliferation in Human Islets
Hui Liu,
1 Maria S. Remedi,
2 Kirk L. Pappan,
1 Guim Kwon,
3 Nidhi Rohatgi,
1 Connie A. Marshall,
1 and
Michael L. McDaniel
1
OBJECTIVE—Our previous studies demonstrated that nutrient
regulation of mammalian target of rapamycin (mTOR) signaling
promotes regenerative processes in rodent islets but rarely in
human islets. Our objective was to extend these ﬁndings by using
therapeutic agents to determine whether the regulation of glyco-
gen synthase kinase-3 (GSK-3)/-catenin and mTOR signaling
represent key components necessary for effecting a positive
impact on human -cell mass relevant to type 1 and 2 diabetes.
RESEARCH DESIGN AND METHODS—Primary adult human
and rat islets were treated with the GSK-3 inhibitors, LiCl and the
highly potent 1-azakenpaullone (1-Akp), and with nutrients. DNA
synthesis, cell cycle progression, and proliferation of -cells
were assessed. Measurement of insulin secretion and content
and Western blot analysis of GSK-3 and mTOR signaling compo-
nents were performed.
RESULTS—Human islets treated for 4 days with LiCl or 1-Akp
exhibited signiﬁcant increases in DNA synthesis, cell cycle
progression, and proliferation of -cells that displayed varying
degrees of sensitivity to rapamycin. Intermediate glucose (8
mmol/l) produced a striking degree of synergism in combination
with GSK-3 inhibition to enhance bromodeoxyuridine (BrdU)
incorporation and Ki-67 expression in human -cells. Nuclear
translocation of -catenin responsible for cell proliferation was
found to be particularly sensitive to rapamycin.
CONCLUSIONS—A combination of GSK-3 inhibition and nutri-
ent activation of mTOR contributes to enhanced DNA synthesis,
cell cycle progression, and proliferation of human -cells. Iden-
tiﬁcation of therapeutic agents that appropriately regulate GSK-3
and mTOR signaling may provide a feasible and available ap-
proach to enhance human islet growth and proliferation.
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ype 1 and 2 diabetes result from the inability of
pancreatic -cells to secrete insulin necessary to
maintain normal glucose homeostasis due to an
acquired secretory defect and/or inadequate
-cell mass (1,2). Studies by Dor et al. (3) and Teta et al.
(4) emphasized the importance of the proliferative capac-
ity of existing adult mouse -cells to signiﬁcantly contrib-
ute to the maintenance of -cell mass during adulthood.
Mammalian target of rapamycin (mTOR) integrates sig-
nals derived from growth factors and nutrients to regulate
protein translation, DNA synthesis, cell size, and prolifer-
ation (5–10). Target of rapamycin complex 1 (TORC1) is a
functional association of mTOR with the scaffolding pro-
tein, raptor, whereas TORC2 is the functional association
of mTOR with the protein, rictor. Rapamycin is able to
disrupt raptor-mTOR interaction, whereas the rictor-
mTOR complex is resistant to short-term exposure to
rapamycin (6). Two prominent downstream targets of
mTOR are 70-kDa ribosomal protein S6 kinase (S6K1) and
eukaryotic initiation factor 4E–binding protein 1 (4EBP1).
The overactivation of mTOR/S6K1 due to excess nutrients
exerts a feedback inhibition through the upstream insulin
receptor substrates 1 and 2 of insulin signaling that leads
to decreased phosphorylation and activity of Akt (1,11).
Glycogen synthase kinase-3 (GSK-3) derives its name
from its ability to phosphorylate glycogen synthase and to
suppress glycogen synthesis in skeletal muscle, but since
this initial observation, a myriad of other GSK-3 targets
have been identiﬁed (12–14). Two isoforms of GSK-3, 
and , exist and have overlapping functions. Lithium, an
agent used as a mood stabilizer for decades, was ﬁrst
connected to GSK-3 inhibition for its ability to mimic Wnt
signaling in Xenopus development (15,16). Lithium also
inhibits inositol monophosphatase and other related
phosphomonoesterases (17). Recently, more speciﬁc and
potent small molecule GSK-3 inhibitors have been devel-
oped, of which 1-azakenpaullone (1-Akp) is among the
most potent and selective (18,19).
Our previous studies demonstrated that glucose,
leucine, cAMP, and modulation of ATP-sensitive K
 (KATP)
channels stimulate mTOR-dependent DNA synthesis and
cell cycle progression in rat islets in a rapamycin-sensitive
manner (20–23). In contrast to rat islets, human islets
exhibited a variable response to these same stimuli, based
on mTOR/S6K1 phosphorylation, and rarely increased
DNA synthesis or entered the cell cycle. Because our
previous studies on nutrient regulation of mTOR in rat
islets identiﬁed a substantial dependence on mitochon-
drial metabolism, we extended our studies to nutrient
metabolites. In preliminary experiments with the
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lithium component in commercially available acetoacetate
salt signiﬁcantly enhanced DNA synthesis and cell cycle
progression in rodent and human islets in a rapamycin-
sensitive manner. These effects of lithium were consistent
with earlier ﬁndings by Sjoholm et al. (24), demonstrating
that lithium triggered DNA synthesis in fetal rat islets,
although the mechanism responsible for this effect was not
identiﬁed. Here, we show that LiCl and the highly potent
and speciﬁc GSK-3 inhibitor, 1-Akp, in combination with
glucose, possess the ability to stimulate mTOR-dependent
DNA synthesis, cell cycle progression, and proliferation of
-cells in human islets.
RESEARCH DESIGN AND METHODS
Lithium chloride (LiCl) was from Sigma, rapamycin was from Biomol, and
1-Akp was from Calbiochem.
Human islets. Human islets were obtained from National Institutes of Health
(NIH)-sponsored Islet Cell Resource (ICR) Basic Science Islet Distribution
Program Centers (see ACKNOWLEDGMENTS for Centers) and the Juvenile Diabe-
tes Research Foundation (JDRF) Human Islet Distribution Program at Wash-
ington University. All studies involving the use of isolated, cadaver-derived
human islets were approved by the Washington University Human Studies
Committee. Human islet donor data are as follows: 27 donors; 10 ICR Centers;
17 men, 10 women; age, mean 43.9 years (range 17–66); BMI, mean 29.3 (range
16.7–44.9); cold ischemia time, mean9h6m i n(range1h2 5m i nt o1 8h2 9
min); purity, mean 72.9% (range 20–95%); and viability, mean 90.3% (range
65–100%). Islets were handpicked for experiments.
Rat islet isolation. Rat islets were obtained from adult male Sprague-Dawley
rats (250 g; Harlan Sprague-Dawley) as previously described (20). Studies
were approved by the Washington University Animal Studies Committee.
[
3H]thymidine incorporation. Islets (100) were cultured in Petri dishes for
4 days in 1 ml Connaught Medical Research Laboratories (CMRL) 1066 media
[8 mmol/l glucose, 10% fetal bovine serum (FBS), 2 mmol/l L-glutamine, 100
units/ml penicillin, and 100 g/ml streptomycin] with treatment conditions as
indicated in the ﬁgure legends at 37°C. During the ﬁnal 24 h of the 96-h
incubation, 10 Ci [
3H]thymidine (Perkin-Elmer) was added, and [
3H]thymi-
dine incorporation was determined by trichloroacetic acid extraction and
scintillation counting.
Flow cytometry. Islets (200) were cultured for 4 days in 1 ml CMRL as
described in the ﬁgure legends. Islets were dispersed with Dispase (Roche) in
Ca
2- and Mg
2-free Hanks solution at 31°C. Cells were rinsed with PBS plus
1% FBS and resuspended in PBS plus 1% FBS containing 250 g/ml RNase
A and 10 g/ml propidium iodide. The DNA content was analyzed using a
FACSCalibur instrument, and data were analyzed with CellQuest software
(20).
Immunohistochemistry. For Ki-67 expression, BrdU incorporation, and
-catenin nuclear translocation, human or rat islets (50–100) were treated for
4 days (1 day for -catenin) and then dispersed using Accutase (Innovative
Cell Technologies), and single-cell suspensions were cytospun onto coated
slides (3,000–4,000 cells/slide). Cells were ﬁxed in 4% paraformaldehyde,
permeabilized using 1% Triton X-100 for 30 min, and blocked with 3% BSA for
1 h at room temperature. Indirect immunoﬂuorescence was performed using
primary antibodies, rabbit anti-insulin (1:100; Cell Signaling), mouse anti–
Ki-67 (1:100; Dako), mouse anti–-catenin (1:2,000; BD Biosciences), and
secondary antibodies, Alexa 488 goat anti-rabbit (1:1,000) and Alexa 555 goat
anti-mouse (1:1,000) (Molecular Probes). Nuclei were counterstained with
4,6-diamindino-2-phenylindole (DAPI; Molecular Probes). Images were ac-
quired using an Olympus BX61W1 microscope equipped with Olympus DP 70
cooled digital color camera.
Parafﬁn-embedded human islet sections (20–30 islets/section) were depar-
afﬁnized using xylene and rehydrated with graded alcohol. Antigen retrieval
was carried out by microwaving the sections in 1 mmol/l EDTA, pH 8.0, for 15
min at high power followed by blocking in 3% BSA for1ha troom
temperature. The primary and secondary antibodies used were the same as
above. For BrdU immunostaining, 1 l cell proliferation labeling reagent
(Amersham) was added to the treatment medium during the last 24 h of the
4-day incubation period and processed according to the manufacturer’s
protocol. Zeiss confocal microscope LSM 510 was used for Z-Stack analysis to
conﬁrm colocalization of Ki-67 or BrdU with insulin in human islets.
Proliferating -cells were reported as the fold increase in Ki-67
 or BrdU

insulin
/insulin
 cells compared with 5 mmol/l glucose. Nuclear translocation
of -catenin in -cells is reported as fold increase in colocalized nuclear
-catenin
 insulin
/insulin
 cells.
Insulin secretion and content. Islets were cultured for 4 days in CMRL
medium containing 10% FBS, 8 mmol/l glucose  5 mmol/l LiCl or 5 mol/l
1-Akp at 37°C. Static insulin secretion and islet insulin content were assayed
as described in the ﬁgure legend.
Western blotting. Islets (100) were incubated in CMRL medium with 0.1%
BSA (1 ml) and treated as indicated in the ﬁgure legends for 30 min. Islet
proteins were resolved by SDS-PAGE, transferred to nitrocellulose, and
immunoblotted using ECL (Amersham) for detection of total and phosphor-
ylated forms of GSK-3 and -3 (Ser 21/9), total -catenin, and phosphorylated
S6 and Akt (Ser473) (Cell Signaling).
Expression of data and statistics. Data are presented as means  SE.
Statistically signiﬁcant differences were assessed with unpaired t tests or
one-way ANOVA followed by Newman-Keuls multiple comparison test. Sig-
niﬁcant differences are indicated by *P  0.05, **P  0.01, and ***P  0.001.
RESULTS
Effects of LiCl and 1-Akp on mTOR-mediated DNA
synthesis. Fig. 1A shows that LiCl at 5 and 10 mmol/l
signiﬁcantly enhanced DNA synthesis in human islets
above that of 8 mmol/l glucose, whereas 15 mmol/l LiCl did
not. Rapamycin (25 nmol/l) signiﬁcantly inhibited DNA
synthesis at all concentrations of LiCl (0, 5, 10, and 15
mmol/l) in the presence of 8 mmol/l glucose. Rapamycin at
100 nmol/l failed to inhibit DNA synthesis below that at 25
nmol/l rapamycin. As shown in Fig. 1B, 1-Akp at 5, 10, and
15 mol/l signiﬁcantly enhanced DNA synthesis in human
islets above that of 8 mmol/l glucose alone. Although 25
nmol/l rapamycin signiﬁcantly inhibited DNA synthesis at
5, 10, and 15 mol/l 1-Akp, the total amount of [
3H]thymi-
dine incorporation continued to rise with increasing doses
of 1-Akp. Rapamycin at 100 nmol/l failed to signiﬁcantly
inhibit DNA synthesis below that of 25 nmol/l rapamycin.
Figure 1C shows that LiCl at 5, 10, and 15 mmol/l
signiﬁcantly enhanced DNA synthesis above that of 8
mmol/l glucose in rat islets and was highly sensitive to
inhibition by rapamycin. Although 1-Akp (Fig. 1D) signiﬁ-
cantly increased DNA synthesis in rat islets above 8
mmol/l glucose alone, it did not continue to rise with
increasing concentrations of 1-Akp in contrast to human
islets (Fig. 1B). Rapamycin (25 nmol/l) signiﬁcantly inhib-
ited DNA synthesis at 0, 5, 10, and 15 mol/l 1-Akp.
Effects of exogenous insulin on DNA synthesis. Figure
2A (ﬁlled columns) indicates that exogenous insulin (2, 20,
or 200 nmol/l) failed to signiﬁcantly increase DNA synthe-
sis in human islets above that of basal glucose (5 mmol/l).
1-Akp (Fig. 2A, open columns) at 10 and 15 mol/l shows
a marked increase in DNA synthesis. These studies sug-
gest that stimulatory actions of 1-Akp on DNA synthesis
are independent of endogenous insulin through the insulin
signaling pathway. Rapamycin (25 nmol/l) signiﬁcantly
reduced DNA synthesis induced by 5 mmol/l glucose
plus 200 nmol/l insulin, even below the levels at 5
mmol/l glucose. 1-Akp–dependent DNA synthesis in
human islets was modestly, but not signiﬁcantly, sensi-
tive to rapamycin.
In contrast to human islets, rat islets (Fig. 2B) show
signiﬁcantly enhanced DNA synthesis at 200 nmol/l insu-
lin. As in human islets (Fig. 2A), 25 nmol/l rapamycin
signiﬁcantly reduced DNA synthesis induced by 5 mmol/l
glucose plus 200 nmol/l insulin. Rapamycin (25 nmol/l)
reduced, whereas 100 nmol/l rapamycin completely inhib-
ited, 15 mol/l 1-Akp–mediated enhancement of DNA
synthesis. Rat islets also incorporated signiﬁcantly more
[
3H]thymidine overall than human islets.
GSK-3 inhibition and cell cycle progression. In Fig. 3A,
exposure of human islets to 10 mmol/l LiCl plus 5 mmol/l
GSK-3 AND mTOR PATHWAYS AND HUMAN ISLET GROWTH
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(data not shown), resulted in a signiﬁcant decrease of
cells in G0/G1 phase (76  1.4 to 55  4.0%), an increase
of cells in S phase (5.4  0.9 to 24  5.0%), and a
retention of cells in G2/M (12%) compared with 5 mmol/l
glucose. Rapamycin (100 nmol/l) prevented the progres-
sion of cells from G0/G1 to S phase.
As shown in Fig. 3B, human islets exposed to 15 mol/l
1-Akp mimicked the stimulatory effects of LiCl on cell
cycle progression (Fig. 3A) in a rapamycin-sensitive man-
ner. There was no detection of increased apoptosis under
these conditions as shown in Fig. 3B.
In Fig. 3C, an increase in glucose from 5 to 8 mmol/l
failed to exert any signiﬁcant effects on G0/G1,S ,o rG 2/M
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FIG. 1. Dose response of LiCl and 1-Akp on mTOR-dependent DNA synthesis in human and rat islets. Human (A and B) or rat (C and D) islets
(100) were cultured for 4 days in CMRL-1066 medium containing 10% FBS, 8 mmol/l glucose  rapamycin, LiCl, or 1-Akp as indicated.
[
3H]thymidine was added to each dish 24 h before the end of the 4-day period. Data are the means  SE; n  3 experiments (except at 15 mmol/l
LiCl n  2) (A); n  5 experiments (except at 15 mol/l 1-Akp n  2) with duplicate or triplicate samples in each experiment (B); n  3 with
duplicate samples in each experiment (C and D). *P < 0.05, **P < 0.01, and ***P < 0.001 indicate signiﬁcant differences from 8 mmol/l glucose
alone. f, 8 mmol/l glucose; , 8 mmol/l glucose  Rap 25 nmol/l; F, 8 mmol/l glucose  Rap 100 nmol/l.
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FIG. 2. Effects of exogenous insulin on mTOR-dependent DNA synthesis in human and rat islets. Human islets (A) or rat islets (B) (100) were
cultured for 4 days in CMRL-1066 medium containing 10% FBS, 5 mmol/l glucose  rapamycin, insulin, or 1-Akp as indicated. [
3H]thymidine was
added to each dish 24 h before the end of the 4-day period. Data are the means  SE of n  3 experiments with triplicate samples in each
experiment. **P < 0.01 and ***P < 0.001 denote signiﬁcant differences between the bracketed conditions. cpm, counts per minute.
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DIABETES, VOL. 58, MARCH 2009 665phases in human islets. In contrast, exposure of human
islets to 8 mmol/l glucose plus 15 mol/l 1-Akp signiﬁ-
cantly decreased cells in G0/G1 and increased cells in S
phase with no change in G2/M. All of these changes were
blocked by rapamycin.
In Fig. 3D, exposure of rat islets to 10 mmol/l LiCl at 5
mmol/l glucose resulted in a signiﬁcant decrease of cells in
G0/G1 phase, an increase of cells in S phase, and a
retention of cells in G2/M. Exposure of rat islets to an
increase of glucose from 5 to 8 mmol/l alone produced a
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FIG. 3. Lithium- and 1-Akp–mediated promotion of cell cycle progression in human and rat islet cells is blocked by rapamycin. Human (A–C) and
rat (D and E) (200) islets were cultured in CMRL containing 10% FBS, 5 or 8 mmol/l glucose, and LiCl or 1-Akp  rapamycin as indicated. At the
end of the 4-day incubation period, islets were dispersed into single cells and processed as described in RESEARCH DESIGN AND METHODS to determine
cell cycle progression. Data are the means  SE of n  2 experiments with duplicate samples in each experiment (A and B; A: , 5 mmol/l glucose;
f, 5 mmol/l glucose  10 mmol/l LiCl; o, 5 mmol/l glucose  10 mmol/l LiCl  100 nmol/l rapamycin. B: , 5 mmol/l glucose; f, 5 mmol/l glucose
 15 mol/l 1-Akp; o, 5 mmol/l glucose  15 mol/l 1-Akp  100 nmol/l rapamycin.), n  3 experiments with duplicate samples (C; , 5 mmol/l
glucose; z, 8 mmol/l glucose; p, 8 mmol/l glucose  100 nmol/l rapamycin; f, 8 mmol/l glucose  15 mol/l 1-Akp; o, 8 mmol/l glucose  15 mol/l
1-Akp  100 nmol/l rapamycin), n  2 experiments with duplicate samples (D; , 5 mmol/l glucose; f, 5 mmol/l glucose  10 mmol/l LiCl; p,
8mmol/l glucose; o, 8 mmol/l glucose  10 mmol/l LiCl), and n  3 experiments with triplicate samples (E; , 5 mmol/l glucose; f, 8 mmol/l glucose;
p, 8 mmol/l glucose  15 mol/l 1-Akp; o, 8 mmol/l glucose  15 mol/l 1-Akp  100 nmol/l rapamycin). **P < 0.01 and ***P < 0.001 denote
signiﬁcant differences between the bracketed conditions.
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glucose. This effect of 8 mmol/l glucose on cell cycle
progression was further increased by LiCl. This demon-
strates the striking effect of glucose on cell cycle progres-
sion in rat islets in contrast to human islets (Fig. 3C). In
Fig. 3E, exposure of rat islets to 8 mmol/l glucose com-
pared with 5 mmol/l glucose resulted in a signiﬁcant
decrease of cells in Go/G1 phase and an increase of cells in
S phase that was further increased by 1-Akp in a rapamycin-
sensitive manner.
Effects of lithium and 1-Akp on insulin secretion and
content. Figure 4A shows that after 4 days, human islets
in all three treatment groups fail to signiﬁcantly increase
insulin secretion in response to 16.5 mmol/l glucose. The
addition of forskolin, to increase cAMP concentrations, in
combination with 16.5 mmol/l glucose signiﬁcantly in-
creased insulin secretion in control and 1-Akp–treated
islets but not with LiCl treatment. Total islet insulin
content on day 4 (Fig. 4B) was signiﬁcantly reduced
compared with time 0 in all three treatment conditions,
however, there were no differences between the treatment
groups on day 4. In contrast, rat islets (Fig. 4C) secrete
insulin in response to glucose in all three treatment
conditions, and no signiﬁcant difference in insulin content
between treatment groups or reduction from time 0 to day
4 was seen (Fig. 4D).
Effects of glucose and GSK-3 inhibitors on -cell
proliferation in human islets. Figure 5B demonstrates
that human islets treated with 5 mmol/l LiCl or 5 mol/l
1-Akp in the presence of 5 or 8 mmol/l glucose alone did
not signiﬁcantly increase the number of Ki-67
/insulin

cells compared with 5 mmol/l glucose alone. However,
combinations of 8 mmol/l glucose with either LiCl or 1-Akp
show signiﬁcant increases in Ki-67
/insulin
 cells com-
pared with basal glucose. Glucose (8 mmol/l) plus LiCl
signiﬁcantly increased the number of Ki-67
/insulin
 cells
compared with that of 8 mmol/l glucose alone or 5 mmol/l
glucose plus LiCl. A fourfold increase in proliferating
-cells was noted in human islets treated with 8 mmol/l
glucose plus LiCl (0.71  0.3%) in contrast to 5 mmol/l
glucose plus LiCl (0.168  0.08%). Rapamycin treatment
resulted in signiﬁcantly fewer Ki-67
/insulin
 cells in all
treatment conditions. Figure 5D shows that glucose and
GSK-3 inhibitors have a similar effect on BrdU labeling in
-cells as observed with Ki-67. Glucose (8 mmol/l) plus
LiCl or 1-Akp also signiﬁcantly increased the number of
BrdU
/insulin
 cells compared with that of 8 mmol/l
glucose alone or 5 mmol/l glucose plus LiCl or 1-Akp.
Figure 5A (left) is a representative confocal image of two
parafﬁn-embedded intact human islets showing colocaliza-
tion of Ki-67
 (red nuclei) and insulin
 (green cytoplasm)
cells. Figure 5A, right panel (inset from left panel)i sa
Z-Stack image magniﬁed to conﬁrm colocalization of Ki-67
and insulin in two adjacent -cells or a dividing -cell.
Figure 5C is a representative image of dispersed human
-cells stained for insulin and BrdU.
GSK-3 and mTOR signaling in human islets. Figure 6A
demonstrates that 10 mmol/l LiCl stimulates the phosphor-
ylation of GSK-3 at both 5 and 8 mmol/l glucose in human
islets. As shown in Fig.6B, LiCl increases accumulation of
-catenin, a downstream target of GSK-3, at 5 mmol/l
glucose that is consistent with GSK-3 inhibition. An in-
crease in glucose from 5 to 8 mmol/l also increases
-catenin accumulation. LiCl fails to further enhance
-catenin accumulation above 8 mmol/l glucose. Although
the stimulatory effect of LiCl on GSK-3 phosphorylation
at basal glucose is rapamycin insensitive, the stimulatory
effects of intermediate glucose in enhancing -catenin
accumulation revealed a small degree of rapamycin sensi-
tivity. In Fig. 6C, an increase in glucose from 5 to 8 mmol/l
failed to exert any signiﬁcant effects on S6 phosphoryla-
tion, an indicator of mTOR activation, and 10 mmol/l LiCl
FIG. 4. Glucose-stimulated insulin secretion and insulin content in human and rat islets. Human (A and B) or rat (C and D) islets were cultured
in CMRL-1066 medium containing 10% FBS, 8 mmol/l glucose  LiCl or 1-Akp as indicated. At the end of 4 days, islets were incubated for1hi n
CMRL containing 5 mmol/l glucose and then four to eight aliquots of 10 islets were counted for each treatment group. Islets were preincubated
for 30 min in CMRL (5 mmol/l glucose), and medium was replaced with CMRL 5, 16.5 mmol/l glucose, or 16.5 mmol/l glucose  10 mol/l forskolin
for 30 min. Supernatants and islet insulin content were assayed by radioimmunoassay. Insulin content from three to four aliquots of 10 islets was
also measured at the start of the incubation period (Time 0). Data are the means  SE from n  3 experiments with duplicate or quadruplicate
samples in each experiment. A and C:* * P < 0.01 and ***P < 0.001 indicate signiﬁcant differences from 5 mmol/l glucose alone or with LiCl or
1-Akp. B: ***P < 0.001 indicates signiﬁcant differences between Time 0 and 4-day incubation with 8 mmol/l glucose alone or with LiCl or 1-Akp.
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rapamycin sensitive.
In Fig. 6D,1 0mol/l 1-Akp stimulated -catenin accu-
mulation at basal glucose in a rapamycin-insensitive
manner. Glucose (8 mmol/l) also enhanced -catenin
accumulation above 5 mmol/l glucose, and 1-Akp did not
further potentiate this increase. Enhanced accumulation
of -catenin by 8 mmol/l glucose and 1-Akp was rapamycin
sensitive. In Fig. 6E, 1-Akp at 5 or 8 mmol/l glucose failed
to increase S6 phosphorylation, and this basal level of S6
phosphorylation was rapamycin sensitive.
We next evaluated the effects of exogenous insulin on
Akt and GSK-3. As shown in Fig. 6F, increasing insulin
from 2 to 200 nmol/l at 5 mmol/l glucose was ineffective in
stimulating Akt phosphorylation. However, coincubation
of human islets with 200 nmol/l insulin plus rapamycin
resulted in a signiﬁcant phosphorylation of Akt, indicating
the presence of a negative feedback inhibition of IRS
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ﬁvefold magniﬁcation to display conﬁrmed colocalization of Ki-67 (red nuclei) and insulin (green cytoplasm) in two adjacent -cells or a dividing
-cell. C: Representative immunoﬂuorescent image of -cell proliferation in dispersed islet cells treated for 4 days with 8 mmol/l glucose with 5
mol/l 1-Akp as measured by BrdU incorporation (red nucleus) in insulin
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tent with an increase in the phosphorylation of GSK-3, a
downstream target of Akt as shown in Fig. 6G.
GSK-3 inhibition and -catenin nuclear transloca-
tion. Because glucose or the GSK-3 inhibitors, LiCl and
1-Akp, increased steady-state levels of -catenin in human
islet cells, we assessed the degree of -catenin transloca-
tion to the nucleus. Figure 7A and B indicate that 10
mmol/l LiCl and 10 mol/l 1-Akp signiﬁcantly increased
nuclear translocation of -catenin in human -cells com-
pared with 5 or 8 mmol/l glucose. Although increasing
glucose from 5 to 8 mmol/l increased -catenin accumu-
lation (Fig. 6B and D), this did not result in the transloca-
tion of -catenin to the nucleus. Unexpectedly, 25 nmol/l
rapamycin strikingly blocked the increase in -catenin
translocation to the nucleus of human islet -cells in the
presence of lithium or 1-Akp. Human -cells (green cyto-
plasm) were identiﬁed as positive for -catenin nuclear
translocation if nuclei were purple (combination of DAPI
blue and -catenin red). This staining pattern for nuclear
-catenin was also reported by Yi et al. (25).
DISCUSSION
The focus of this study was to identify signaling pathways
and potential therapeutic agents that would allow repro-
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FIG. 6. GSK-3 and mTOR signaling in human
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sion, and proliferation in human -cells. We found that
glucose, mTOR activity, and inhibition of GSK-3 together
stimulated these regenerative processes in a highly repro-
ducible manner in adult human -cells regardless of sex,
age, BMI, or isolation center.
Both LiCl and 1-Akp signiﬁcantly enhanced DNA
synthesis above that of 8 mmol/l glucose, and LiCl-
mediated DNA synthesis was more sensitive to rapamy-
cin than 1-Akp. This ﬁnding suggested that a component
of 1-Akp–stimulated DNA synthesis in human islets is
mTOR independent. Although lithium at higher concen-
trations decreased DNA synthesis in human islets, this
did not appear to be due to apoptosis because cell cycle
analysis (Fig. 3A and B) failed to detect a signiﬁcant
degree of apoptosis under similar conditions. Muss-
mann et al. (18) reported that lithium produces toxic
effects at concentrations 	3 mmol/l in the cell line,
INS-1E, but this is not the case in human or rodent
islets. Our studies also determined that the increase in
DNA synthesis induced by lithium and 1-Akp in human
islets was not due to the effects of endogenous insulin
through the insulin signaling pathway (Fig. 2A).
At basal glucose, lithium and 1-Akp produced a similar
magnitude of entry of human and rat islet cells into the cell
cycle. Human islet cells did not enter the cell cycle in
response to 8 mmol/l glucose but required GSK-3 inhibi-
tion. In contrast, rat islets cells entered the cell cycle in
response to 8 mmol/l glucose, which was further increased
by both lithium and 1-Akp.
Although human islets treated for 4 days with 8 mmol/l
glucose  1-Akp secreted insulin in response to 16.5
mmol/l glucose plus forskolin, a signiﬁcant loss of insulin
content in human islets occurred as a consequence of the
4-day culture in all treatment conditions. Efrat and col-
leagues (26) found that expanding dispersed human islets
resulted in lower levels of insulin content, but subsequent
treatment with -cellulin resulted in redifferentiation with
restoration of -cell gene expression and insulin content.
Although our treatment conditions enhance expansion of
human -cells, this strategy alone may not be optimal to
maintain or restore differentiation. Our immunohisto-
chemical analysis of the colocalization of Ki-67 or BrdU
with insulin has provided insights into this objective. A
number of human -cells positive for Ki-67 or BrdU had
only a few insulin granules in the cytoplasm (Fig. 5E).
Such poorly granulated cells were not included in our
proliferation data, which may be an underestimation of
actual human -cell proliferation. This population of
-cells will be the focus of future studies aimed at main-
taining or restoring insulin gene expression.
Studies also focused on gaining insights into the signal-
ing mechanism whereby GSK-3 inhibition affects DNA
synthesis, cell cycle progression, and proliferation in a
rapamycin-sensitive manner. We observed that GSK-3 in-
hibition, in the presence of 5 or 8 mmol/l glucose, resulted
in increases in -catenin accumulation and translocation,
whereas an increase in glucose concentration alone re-
sults only in -catenin accumulation. The increase in
-catenin accumulation due to an increase in glucose
concentration showed a small degree of rapamycin sensi-
tivity. Importantly, -catenin translocation in response to
GSK-3 inhibition was signiﬁcantly rapamycin sensitive and
may represent an important mechanism responsible for
the ability of rapamycin to inhibit DNA synthesis, cell
cycle progression, and -cell proliferation. Recent studies
proposed that -catenin signaling is both necessary and
sufﬁcient for -cell proliferation in mouse islets (27) and
that overexpression of GSK-3 in mice reduces -cell mass
(28). However, these studies did not address the role of
mTOR in combination with -catenin signaling as a re-
quirement for rodent -cell proliferation. In addition,
Wnt3a treatment failed to stimulate human -cell prolifer-
ation (27), suggesting that a more direct inhibition of
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see http://dx.doi.org/10.2337/db07-1208 for a high-quality digital repre-
sentation of this ﬁgure.)
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mann et al. (18) demonstrated that GSK-3 inhibitors, 1-Akp
and CHIR99021, promoted rat -cell replication over the
range of 1–20 mol/l after 72-h incubation. These studies
did not examine the effects of these inhibitors or the
contribution of the nutrient glucose and the mTOR path-
way in promoting human -cell proliferation.
Recent studies by Inoki et al. (29) and Jin et al. (30) have
identiﬁed in non–-cells a key role for GSK-3, in a -cate-
nin–independent manner, to regulate mTOR signaling.
They suggest that enhanced GSK-3 and AMP-activated
protein kinase (AMPK) activities cooperate in the activa-
tion of TSC2 to inhibit mTOR activity. Collectively, their
studies indicate that inhibition of GSK-3 is required for
mTOR activation. Thus, we next examined whether GSK-3
inhibition has a positive effect on mTOR activation in
human islets. GSK-3 inhibition exerted inconsistent and
small effects on mTOR signaling in the presence of 5 or 8
mmol/l glucose (Fig. 6C and E). In the absence of glucose,
GSK-3 inhibitors resulted in a small increase in S6 phos-
phorylation (data not shown). As shown in Fig. 8, both
phosphorylation of GSK-3 and a decrease in AMPK due to
increased nutrient metabolism play a key role in inhibiting
TSC1/2 and in turn activate the mTOR pathway. Although
our data demonstrate the existence of this pathway in
primary islets, it is unclear at this point what role GSK-3
plays in mTOR regulation.
In contrast, mTOR exerts multiple effects on GSK-3
signaling in human -cells (Fig. 8). Chronic overactivation
of mTOR/S6K1 leads to a negative feedback of the insulin
signaling pathway and reduced Akt phosphorylation and
indirectly activates GSK-3. Insulin dose responses (Figs. 2
and 6F and G) revealed that human islets failed to signal
through the insulin signaling cascade. This suggests that
under these in vitro conditions, human islets exhibit a
relatively high level of insulin resistance. Furthermore,
rapamycin restores insulin sensitivity, suggesting that
even basal levels of mTOR activation sufﬁciently engage
feedback inhibition of the insulin signaling cascade in
human islets, resulting in insulin resistance. Zhang et al.
(31) propose that mTOR-dependent feedback inhibition of
Akt may also result in a feedforward mechanism to
regulate GSK-3 in the absence of Akt input. Although our
studies show that 8 mmol/l glucose increases -catenin
accumulation, suggesting that this feedforward mecha-
nism may regulate GSK-3/-catenin in human islets, it is
unclear why this does not result in detectable -catenin
nuclear translocation.
Signiﬁcant ﬁndings reported here are the synergistic
effects of 8 mmol/l glucose and GSK-3 inhibition to en-
hance human -cell proliferation. In addition, the rapamy-
cin sensitivity of -catenin nuclear translocation may
explain, in part, the mechanism whereby rapamycin inhib-
its these regenerative processes. Our data suggest that
although mTOR activity is necessary, even basal levels
may result in engagement of negative feedback from S6K1
and result in a relatively high constitutive level of GSK-3
activity in human islets in vitro. This may explain the need
for direct inhibition of GSK-3 with therapeutic agents.
Overall, these studies suggest that appropriate regulation
of mTOR and GSK-3/-catenin signaling in combination
with strategies to maintain or restore differentiation may
provide available approaches to expand human -cell
mass.
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